NATERA ($NTRA) posted quarterly earnings results on Thursday, August 7th. The company reported earnings of -$0.74 per share, missing estimates of -$0.63 by $0.11. The company also reported revenue of $546,600,000, beating estimates of $485,815,912 by $60,784,088.
You can see Quiver Quantitative's $NTRA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NATERA Insider Trading Activity
NATERA insiders have traded $NTRA stock on the open market 216 times in the past 6 months. Of those trades, 0 have been purchases and 216 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 30 sales selling 159,257 shares for an estimated $22,983,648.
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 15 sales selling 108,563 shares for an estimated $16,435,622.
- JONATHAN SHEENA has made 0 purchases and 72 sales selling 36,958 shares for an estimated $5,671,407.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 31 sales selling 30,306 shares for an estimated $4,528,042.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 12 sales selling 27,161 shares for an estimated $4,439,339.
- GAIL BOXER MARCUS has made 0 purchases and 22 sales selling 22,795 shares for an estimated $3,469,952.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 25 sales selling 19,024 shares for an estimated $2,745,637.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 9 sales selling 6,997 shares for an estimated $1,055,805.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NATERA Hedge Fund Activity
We have seen 345 institutional investors add shares of NATERA stock to their portfolio, and 309 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 3,795,315 shares (+56.3%) to their portfolio in Q1 2025, for an estimated $536,695,494
- BLACKROCK, INC. added 1,260,125 shares (+13.7%) to their portfolio in Q1 2025, for an estimated $178,194,276
- KYNAM CAPITAL MANAGEMENT, LP removed 854,528 shares (-42.3%) from their portfolio in Q1 2025, for an estimated $120,838,804
- GOLDMAN SACHS GROUP INC removed 734,551 shares (-43.3%) from their portfolio in Q1 2025, for an estimated $103,872,856
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 732,156 shares (+140.4%) to their portfolio in Q1 2025, for an estimated $103,534,179
- CITADEL ADVISORS LLC added 691,990 shares (+48.4%) to their portfolio in Q1 2025, for an estimated $97,854,305
- JPMORGAN CHASE & CO added 660,538 shares (+9.9%) to their portfolio in Q1 2025, for an estimated $93,406,678
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NATERA Government Contracts
We have seen $766,142 of award payments to $NTRA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- NEW TASK ORDER TO EXTEND THE POP FOR SIX (6) MONTHS: $499,447
- MODIFICATION TO EXTEND THE POP FOR SIX (6) MONTHS: $140,595
- GENETIC TESTING: $79,200
- TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $46,900
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
NATERA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 07/28/2025
- Piper Sandler issued a "Overweight" rating on 05/15/2025
- Barclays issued a "Overweight" rating on 05/09/2025
- UBS issued a "Buy" rating on 05/09/2025
- RBC Capital issued a "Outperform" rating on 03/13/2025
- Morgan Stanley issued a "Overweight" rating on 03/05/2025
- Canaccord Genuity issued a "Buy" rating on 02/28/2025
To track analyst ratings and price targets for NATERA, check out Quiver Quantitative's $NTRA forecast page.
NATERA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 8 analysts offer price targets for $NTRA in the last 6 months, with a median target of $192.5.
Here are some recent targets:
- Daniel Markowitz from Evercore ISI Group set a target price of $170.0 on 07/28/2025
- David Westenberg from Piper Sandler set a target price of $210.0 on 05/15/2025
- Elizabeth Garcia from UBS set a target price of $218.0 on 05/09/2025
- Luke Sergott from Barclays set a target price of $190.0 on 05/09/2025
- Conor McNamara from RBC Capital set a target price of $251.0 on 03/13/2025
- Tejas Savant from Morgan Stanley set a target price of $185.0 on 03/05/2025
- Kyle Mikson from Canaccord Genuity set a target price of $195.0 on 02/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
.jpg)